2022
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT, Verma A. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. ELife 2022, 11: e78136. PMID: 36040792, PMCID: PMC9427103, DOI: 10.7554/elife.78136.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeNF-kB activationLymphoma SocietyMDS/acute myeloid leukemiaNational InstitutePathogenesis of MDSInterleukin-1 receptor-associated kinase 4Expression of IRAK4Inflammatory-immune pathwaysInflammatory cytokine productionSpecific oncogenic pathwaysCareer development grantsHealth research trainingCritical downstream mediatorCytokine productionMyeloid leukemiaPreclinical modelsNew York State DepartmentXenograft modelImmune pathwaysNF-kB.MDS samplesTRAF6 activationLeukemic growth
2018
Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes
Ali AM, Huang Y, Pinheiro RF, Xue F, Hu J, Iverson N, Hoehn D, Coutinho D, Kayani J, Chernak B, Lane J, Hillyer C, Galili N, Jurcic J, Mohandas N, An X, Raza A. Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. Blood Advances 2018, 2: 1393-1402. PMID: 29903708, PMCID: PMC6020814, DOI: 10.1182/bloodadvances.2018018440.Peer-Reviewed Original ResearchConceptsIndependent prognostic markerMyelodysplastic syndromeOverall survivalPrognostic markerMultivariable Cox proportional hazards regression analysisCox proportional hazards regression analysisPowerful independent prognostic markerInternational Prognostic Scoring SystemProportional hazards regression analysisMyeloid/erythroid ratioTerminal erythroid differentiationIPSS-R categoryPrognostic scoring systemHazards regression analysisWorse overall survivalPoor overall survivalBone marrow samplesSurface expressionMost patientsProportion of cellsErythroid ratioMarrow samplesErythroid differentiationSRSF2 mutationsMDS samples
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply